BACKGROUND: The doubling time is the number of chronological years for the age-specific incidence rate to double in magnitude. Doubling times describe the rate of increase of the risk of Alzheimer's disease (AD) with advancing age. Estimates of doubling times of AD assist in understanding disease etiology and forecasting future disease prevalence. The objective of this study was to investigate regional and gender differences in the doubling of AD age-specific incidence rates. METHODS: We identified all studies in the peer review literature that reported age-specific incidence rates for AD. We modeled the logarithm of the incidence rate as a linear function of age. We used both fixed effects models and random effects models to account for interstudy variation. RESULTS: AD incidence rates exponentially increase with increasing age. The overall estimate of the doubling time was 5.5 years. The doubling times from studies performed in North America and Europe were 6.0 and 5.8, respectively; whereas the doubling times in all other parts of the world were 5.0. There was no significant geographic differences in doubling times (P = .3). Although the doubling times were slightly longer for men (6.5 years) than for women (5.4 years), the difference was not significant (P = .3). CONCLUSIONS: Doubling times of AD incidence rates are not statistically significantly different among populations throughout the world. The risk of AD grows exponentially with age, doubling approximately every 5 to 6 years. Although the shapes of the incidence curves are similar, there is considerable variation in absolute incidence rates throughout the world. Currently, there are limited epidemiologic data at the oldest ages, and further study is needed to accurately define the incidence curve above age 90.
BACKGROUND: The doubling time is the number of chronological years for the age-specific incidence rate to double in magnitude. Doubling times describe the rate of increase of the risk of Alzheimer's disease (AD) with advancing age. Estimates of doubling times of AD assist in understanding disease etiology and forecasting future disease prevalence. The objective of this study was to investigate regional and gender differences in the doubling of AD age-specific incidence rates. METHODS: We identified all studies in the peer review literature that reported age-specific incidence rates for AD. We modeled the logarithm of the incidence rate as a linear function of age. We used both fixed effects models and random effects models to account for interstudy variation. RESULTS:AD incidence rates exponentially increase with increasing age. The overall estimate of the doubling time was 5.5 years. The doubling times from studies performed in North America and Europe were 6.0 and 5.8, respectively; whereas the doubling times in all other parts of the world were 5.0. There was no significant geographic differences in doubling times (P = .3). Although the doubling times were slightly longer for men (6.5 years) than for women (5.4 years), the difference was not significant (P = .3). CONCLUSIONS: Doubling times of AD incidence rates are not statistically significantly different among populations throughout the world. The risk of AD grows exponentially with age, doubling approximately every 5 to 6 years. Although the shapes of the incidence curves are similar, there is considerable variation in absolute incidence rates throughout the world. Currently, there are limited epidemiologic data at the oldest ages, and further study is needed to accurately define the incidence curve above age 90.
Authors: Zaven S Khachaturian; Jordi Camí; Sandrine Andrieu; Jesús Avila; Mercè Boada Rovira; Monique Breteler; Lutz Froelich; Serge Gauthier; Teresa Gómez-Isla; Ara S Khachaturian; Lewis H Kuller; Eric B Larson; Oscar L Lopez; José Manuel Martinez-Lage; Ronald C Petersen; Gerard D Schellenberg; Jordi Sunyer; Bruno Vellas; Lisa J Bain Journal: Alzheimers Dement Date: 2009-07 Impact factor: 21.566
Authors: Emily H Trittschuh; Paul K Crane; Eric B Larson; Brenna Cholerton; Wayne C McCormick; Susan M McCurry; James D Bowen; Laura D Baker; Suzanne Craft Journal: J Alzheimers Dis Date: 2011 Impact factor: 4.472
Authors: Karin E Sandoval; Susan A Farr; William A Banks; Albert M Crider; John E Morley; Ken A Witt Journal: Eur J Pharmacol Date: 2012-03-16 Impact factor: 4.432
Authors: Matthias Brendel; Oliver Pogarell; Guoming Xiong; Andreas Delker; Peter Bartenstein; Axel Rominger Journal: Eur J Nucl Med Mol Imaging Date: 2015-01-29 Impact factor: 9.236
Authors: H Davtyan; M Mkrtichyan; N Movsesyan; I Petrushina; G Mamikonyan; D H Cribbs; M G Agadjanyan; A Ghochikyan Journal: Gene Ther Date: 2009-10-29 Impact factor: 5.250
Authors: C Díaz-Ruiz; J Wang; H Ksiezak-Reding; L Ho; X Qian; N Humala; S Thomas; P Martínez-Martín; G M Pasinetti Journal: Cardiovasc Psychiatry Neurol Date: 2009-09-17